Myrtelle Announces Significant Reduction in N-Acetylaspartate (NAA), a Key Biomarker, in Patients Treated in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.
Article Date
October 1, 2024
This article is featured on another website.
Go to article
June 23, 2026
HiRO at BIO Asia–Taiwan: Advancing Global Clinical Development Together
Collaborating Across APAC at BIO Asia–Taiwan to Advance High‑Quality Cross‑Border Clinical Research Harvest Integrated Research…
June 23, 2026
HiRO at BIO Asia–Taiwan: Advancing Global Clinical Development Together
Collaborating Across APAC at BIO Asia–Taiwan to Advance High‑Quality Cross‑Border Clinical Research Harvest Integrated Research…